Fosamax and Osteonecrosis of the Jaw: Causation, Risk Factors, and What Studies Show
Latest update (2026-05)
FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]
From General Health Information to Occupational Exposure Considerations
The legacy of general health and science information has long emphasized the importance of evidence-based prevention and patient education across broad medical contexts. Within this heritage, the dissemination of knowledge regarding medication safety and adverse effects has been a cornerstone, guiding both clinical practice and public awareness. As this informational foundation evolved, it increasingly recognized the need to address specific, high-consequence risks associated with widely prescribed therapies. This progression naturally leads to a focused examination of occupational and environmental exposures that may intersect with pharmaceutical use. In the domain of mass production, where workers may encounter chemical agents or biological materials, the potential for compounded health risks becomes a critical concern. The transition from general health literacy to occupational exposure consideration requires a careful assessment of how workplace factors can influence individual susceptibility to medication-related adverse events. This pivot acknowledges that while general health information provides a baseline, the unique conditions of mass production environments demand specialized attention to exposure pathways and risk mitigation strategies. Thus, the focus shifts from broad health education to the specific intersection of occupational settings and pharmaceutical safety, setting the stage for a detailed exploration of exposure-related risks.
Understanding Fosamax and Its Mechanism of Action
Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its pharmacological action involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a recognized adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation of ONJ involves bone exposure in the oral cavity, often accompanied by pain, swelling, and infection. Diagnosis is typically based on clinical examination and imaging, with a focus on ruling out other causes such as malignancy or radiation-induced osteonecrosis. The condition is considered a rare but serious adverse effect of antiresorptive therapy.
Mechanistic Pathways Linking Fosamax to ONJ
The mechanistic pathways linking Fosamax to ONJ are not fully elucidated but are believed to involve the drug's potent inhibition of osteoclast activity. Bisphosphonates like alendronate accumulate in bone, particularly in areas of high turnover such as the jaw, and suppress bone remodeling. This suppression can impair the ability of the jawbone to repair microdamage and respond to local stressors, such as dental procedures or infection. A multiscale characterization of jawbone has provided comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research suggests that the unique structural and cellular properties of the jawbone may make it particularly susceptible to the effects of bisphosphonates.
Risk Factors and Epidemiological Evidence
The risk of ONJ in patients taking Fosamax is influenced by several factors. Known risk factors include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). A cohort study among female patients treated for osteoporosis in the United Kingdom found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). However, absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/).
Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific warning about ONJ. The label states that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and that it is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the optimal duration of use for Fosamax has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use is considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Causation-related considerations for affected patients involve assessing the temporal relationship between Fosamax use and the development of ONJ, as well as the presence of other risk factors. The evidence indicates that ONJ is a rare adverse effect, and the absolute risk remains low even with prolonged use. However, the risk increases with duration of exposure, and the condition can occur after a variable timeline. For patients who develop ONJ, discontinuation of Fosamax may lead to symptom relief, but recurrence can occur with rechallenge. The decision to continue or discontinue therapy should be made on a case-by-case basis, weighing the benefits of osteoporosis treatment against the risk of ONJ. In summary, the evidence supports a causal association between Fosamax use and ONJ, with risk influenced by duration of exposure and other factors. The prescribing information provides warnings about this risk, but the absolute risk remains low. Patients and healthcare providers should be aware of the signs and symptoms of ONJ and consider preventive dental care and appropriate management strategies.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is Fosamax and how does it work?
Fosamax (alendronate) is a bisphosphonate medication used to treat and prevent osteoporosis, increase bone mass in men with osteoporosis, treat glucocorticoid-induced osteoporosis, and treat Paget's disease of bone. It works by inhibiting bone resorption, thereby increasing bone mass and reducing fracture incidence (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).
What is osteonecrosis of the jaw (ONJ) and how is it related to Fosamax?
ONJ is a condition characterized by exposed, non-healing bone in the jaw, often associated with tooth extraction or local infection. It is a recognized adverse effect of bisphosphonates like Fosamax. The risk increases with longer duration of use and other factors such as invasive dental procedures, cancer diagnosis, and poor oral hygiene (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).
How common is ONJ in patients taking Fosamax?
ONJ is rare. A cohort study found that absolute risk was approximately 0.05% after 5 years of treatment, though the risk increases with duration: threefold higher after 2-3 years and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/).
What are the risk factors for developing ONJ while on Fosamax?
Risk factors include invasive dental procedures (e.g., tooth extraction, implants), cancer, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, pre-existing dental disease, anemia, coagulopathy, infection, and ill-fitting dentures. Longer duration of bisphosphonate use also increases risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).
What should I do if I develop symptoms of ONJ while taking Fosamax?
If you experience jaw pain, swelling, or exposed bone, consult your healthcare provider immediately. They may recommend discontinuing Fosamax and provide appropriate management. Most patients experience relief after stopping the drug, but recurrence can occur with rechallenge (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Free Case & Eligibility Review
Individuals with documented Fosamax exposure and a related diagnosis may request an independent, no-cost eligibility review.